Zobrazeno 1 - 10
of 561
pro vyhledávání: '"J. Appleman"'
Autor:
Tian Zhang, Nicholas J Vogelzang, Daniel P Petrylak, Ravi A Madan, Karen A Autio, Ray Li, Helen Cho, Szu-Yu Tang, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Xin-Hua Zhu, Hani Babiker, Sandip M Prasad, Michael T Schweizer, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Kam Chan, Megan Kaneda, I-Ming Wang, Jenny Zheng, Robert Hollingsworth, Kenneth A Kern
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).Methods For dose escal
Externí odkaz:
https://doaj.org/article/a4a8a3a078ab4567a1641ae4c2b5d1db
Autor:
Monica K. Malhotra, Shalu Pahuja, Brian F. Kiesel, Leonard J. Appleman, Fei Ding, Yan Lin, Hussein A. Tawbi, Ronald G. Stoller, James J. Lee, Chandra P. Belani, Alice P. Chen, Vincent L. Giranda, Stacie Peacock Shepherd, Leisha A. Emens, S. Percy Ivy, Edward Chu, Jan H. Beumer, Shannon Puhalla
Publikováno v:
Breast Cancer Research and Treatment. 198:487-498
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::807df4048513cc6c111834d7987ddddd
https://doi.org/10.1007/s10549-023-06889-0
https://doi.org/10.1007/s10549-023-06889-0
Autor:
Vadim S. Koshkin, Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, Sumanta K. Pal, JoAnn Hsu, Leonard J. Appleman, Moshe C. Ornstein, Timothy Gilligan, Petros Grivas, Jorge A. Garcia, Brian I. Rini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-7 (2018)
Abstract Background Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these pa
Externí odkaz:
https://doaj.org/article/bbc492fd73414e95b44026496b015f42
Autor:
Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola J. Lawrence, Robert Motzer, Bradley McGregor, Richard J. Lee, Rohit K. Jain, Nancy Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begoña Mellado, Juan Manuel Sepúlveda Sánchez, Robert Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier
Publikováno v:
JAMA oncology. 8(10)
ImportanceDysregulated metabolism is a hallmark of renal cell carcinoma (RCC). Glutaminase is a key enzyme that fuels tumor growth by converting glutamine to glutamate. Telaglenastat is an investigational, first-in-class, selective, oral glutaminase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d814d8a9fe7e9265f06d2c12c2ccd89d
https://pubmed.ncbi.nlm.nih.gov/36048459
https://pubmed.ncbi.nlm.nih.gov/36048459
Autor:
Evan Y. Yu, Michael P. Kolinsky, William R. Berry, Margitta Retz, Loic Mourey, Josep M. Piulats, Leonard J. Appleman, Emanuela Romano, Gwenaelle Gravis, Howard Gurney, Martin Bögemann, Urban Emmenegger, Anthony M. Joshua, Mark Linch, Srikala Sridhar, Henry J. Conter, Brigitte Laguerre, Christophe Massard, Xin Tong Li, Charles Schloss, Christian H. Poehlein, Johann S. de Bono
Publikováno v:
European Urology. 82:22-30
Patients with metastatic castration-resistant prostate cancer (mCRPC) frequently receive docetaxel after they develop resistance to abiraterone or enzalutamide and need more efficacious treatments.To evaluate the efficacy and safety of pembrolizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa4643d037afae5e03bf2fb4cc807f9
https://doi.org/10.1016/j.eururo.2022.02.023
https://doi.org/10.1016/j.eururo.2022.02.023
Autor:
Leonidas N. Diamantopoulos, Dimitrios Korentzelos, Michail Alevizakos, Jonathan L. Wright, Petros Grivas, Leonard J Appleman
Publikováno v:
Clinical Genitourinary Cancer. 20:139-147
Sarcomatoid urothelial carcinoma (SUC) is a rare and aggressive variant of bladder cancer with limited data regarding epidemiology and survival. In this study, we explored clinicopathologic factors and oncologic outcomes of patients with SUC derived
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::257ae24cd563a646349fb55183e15a5f
https://doi.org/10.1016/j.clgc.2021.12.015
https://doi.org/10.1016/j.clgc.2021.12.015
Autor:
Susan E. Bates, Jan H. Beumer, Edward Chu, Julie Eiseman, Chandra P. Belani, Yixing Jiang, David R. Kohler, Richard Piekarz, John J. Wright, William M. Bonner, Asako J. Nakamura, Christophe E. Redon, Christine Bryla, Robert A. Parise, Sanjeeve Balasubramaniam, Leonard J. Appleman
Supplementary Tables 1-3. Supplemental Table 1. Plasma pharmacokinetics of DMS612 metabolites. Supplemental Table 2. Pharmacodynamic assessment of !-H2AX detection in PBMCs. Mean values for !-H2AX foci per cell with DMS612 doses of 1.5, 3, 5, 7, 9 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6acbe4e4740497e7dc390afc20e3a505
https://doi.org/10.1158/1078-0432.22459742.v1
https://doi.org/10.1158/1078-0432.22459742.v1
Autor:
Ravi K. Amaravadi, Lisa E. Davis, Phyllis A. Gimotty, Jeremy P. Segal, Sabah Kadri, Chao Jie Zhen, Taehyong Kim, Anusha Kalavacharla, Angelique Onorati, Xiaowei Xu, Melissa Wilks, Maryann Redlinger, Mark Stein, Leonard J. Appleman, Naomi B. Haas
Supplemental Figures 1 and 2 (S1. Measurement of autophagic vesicles in PBMC and S2 Massively parallel sequencing and outcome.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80059cd2f0c13b3518f1367699514395
https://doi.org/10.1158/1078-0432.22472088
https://doi.org/10.1158/1078-0432.22472088
Autor:
Susan E. Bates, Jan H. Beumer, Edward Chu, Julie Eiseman, Chandra P. Belani, Yixing Jiang, David R. Kohler, Richard Piekarz, John J. Wright, William M. Bonner, Asako J. Nakamura, Christophe E. Redon, Christine Bryla, Robert A. Parise, Sanjeeve Balasubramaniam, Leonard J. Appleman
Supplementary Tables 1-3. Supplemental Table 1. Plasma pharmacokinetics of DMS612 metabolites. Supplemental Table 2. Pharmacodynamic assessment of !-H2AX detection in PBMCs. Mean values for !-H2AX foci per cell with DMS612 doses of 1.5, 3, 5, 7, 9 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ba32d1447dceac41dec2087dbd87fa2
https://doi.org/10.1158/1078-0432.22459736
https://doi.org/10.1158/1078-0432.22459736
Autor:
Daniel P. Petrylak, Andrew J. Armstrong, Asim Datye, Kobe C. Yuen, Edward E. Kadel, Darren Tayama, Raphaelle Porcu, Ulka Vaishampayan, Winston Tan, Leonard J. Appleman, Ajjai Alva, Lance Pagliaro, Celestia S. Higano, Oliver Sartor, Michael J. Morris, Lawrence Fong
Supplementary Figures and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::083d501704a59cb05d13aa8632f4dce5
https://doi.org/10.1158/1078-0432.22481508.v1
https://doi.org/10.1158/1078-0432.22481508.v1